SCHEMBL6420149

SCHEMBL6420149

COc1ccc(C(=O)N2c3ccccc3C(N3CCSc4ccccc43)=CC2C)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.51
BCHE P06276 3/20 0.47
ACHE P22303 3/20 0.47
SHMT2 P34897 1/20 0.46
ALDH1A1 P00352 4/20 0.44
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
TSHR P16473 1/20 0.41
MAPT P10636 3/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
TP53 P04637 1/20 0.37
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419389 0.83 PDE4A (0.59) MCL1ALDH1A1PDE4APDE4BPDE4C
SCHEMBL6420070 0.82 PDE4A (0.56) MCL1BCHEACHEALDH1A1PDE4A
SCHEMBL6434898 0.80 MCL1 (0.56) MCL1BCHEACHEALDH1A1PDE4A
SCHEMBL6421831 0.80 PDE4A (0.46) MCL1BCHEACHEALDH1A1PDE4A
SCHEMBL6420033 0.79 MCL1 (0.57) MCL1BCHEACHEALDH1A1PDE4A
SCHEMBL6421092 0.79 MCL1 (0.51) MCL1BCHEACHEPDE4APDE4B
SCHEMBL6420072 0.73 MCL1 (0.53) MCL1BCHEACHESHMT2ALDH1A1
SCHEMBL6420547 0.70 MCL1 (0.73) MCL1BCHEACHEALDH1A1PDE4A
SCHEMBL6425432 0.67 MEN1 (0.66) MCL1BCHEACHEALDH1A1PDE4A
SCHEMBL31318530 0.67 SHMT2 (0.57) BCHEACHESHMT2ALDH1A1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930104-B2 Heterocyclic derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040157850-A1 Novel heterocyclic derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
EP-1382598-A1 NOVEL HETEROCYCLIC DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157850-A1 Novel heterocyclic derivatives APP, BACE1, PSEN1 MCL1 3567/4885BCHE 421/4885ACHE 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.